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The economic evaluations presented in this thesis focused on interventions for 
persons who were diagnosed with major depressive disorder or schizophrenia. 
These disorders are considered to be among the most disabling (mental) illnesses, 
and are both associated with intensive healthcare utilisation and considerable costs 
for society. At the time when the presented studies were initiated, detailed 
information on economic aspects of interventions in mental healthcare was 
virtually absent for the Netherlands, and economic studies in the described patient 
populations were strongly needed to support policy decisions. The primary aim of 
the conducted studies was therefore to assess the cost-effectiveness of the 
interventions concerned and report results to decision-makers.  
In the following section, the overall findings and interpretation of the economic 
evaluations that are part of this thesis will be discussed. The policy decisions that 
were based on these results will also be provided. Various methodological issues 
encountered in these evaluations will be presented in the context of the current 
literature. Based on the discussed methodological issues, recommendations will be 
made for the general design of future economic evaluations in the field of mental 
healthcare. Finally, recent (inter)national developments and economic benefits 
related to various other interventions studied in mental healthcare will be 
discussed, together with the relevance of improving the actual implementation of 




Overall findings and the interpretation of results 
 
Chapters 2 through 5 presented the results of four cost-effectiveness studies in 
patients with major depressive disorder or schizophrenia. In these studies, a wide 
variety of interventions was compared with care as usual (CAU) in the patient 
populations concerned. Two interventions were aimed at depression: Cognitive 
Self-Therapy (Chapter 3) and a depression recurrence prevention programme 
(PEP: Chapter 4). The other two studies addressed interventions in patients with 
schizophrenia: Hallucination focused Integrative Treatment (HIT: Chapter 2) and 
guided discontinuation strategy (Chapter 5).  
For two interventions (HIT and Cognitive Self-Therapy), costs and health 
outcomes were in favour of the interventions under study, although differences 
with CAU in terms of primary health outcomes were generally modest. Results of 
the study comparing three variants of PEP with CAU showed that basic PEP was 
associated with higher costs and worse health outcomes than CAU. Two enhanced 
versions of PEP (with psychiatric consultation and cognitive behavioural therapy) 
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also led to higher costs, but results of the primary health outcome were slightly 
better than in CAU. In the study on discontinuation strategy, no relevant 
differences could be found for costs or health outcomes when comparing results 
with CAU. 
Besides simple comparisons of costs and health outcomes, various additional 
economic analyses were performed in the presented studies. These analyses 
included the calculation of incremental cost-effectiveness ratios as well as 
bootstrap analyses to provide information on the uncertainty surrounding the 
economic results. Furthermore, cost-effectiveness acceptability curves were 
assessed in most studies, which provided information on the probability of the 
interventions being cost-effective. This probability is based on what a decision-
maker (or society) is willing to pay for an additional unit of health outcome (1).  
Interpretation of the overall results of the various conducted economic analyses 
depends on whether one adopts a Bayesian decision-making framework, or applies 
a classical frequentist (statistical hypotheses testing) approach for inference (2). 
When using a frequentist approach, none of the interventions examined in this 
thesis can be considered cost-effective, i.e. there were no statistically significant 
differences for combined cost and health outcomes in any of the four studies. In 
fact, only few published economic evaluations would fulfil such frequentist 
criteria. Various authors have strongly argued for a Bayesian approach in recent 
years, which allows for probability statements that seem more relevant and 
appropriate in the context of decision-making (3). When interpreting the current 
results from a Bayesian perspective, HIT appears to be a cost-effective intervention 
for patients with persistent auditory hallucinations in comparison with CAU. 
Furthermore, the results of the economic analyses in the Cognitive Self-Therapy 
study are in support of implementing this intervention in the Dutch healthcare 
system. Interpretation of the economic results of the study on PEP is not favourable 
for the basic PEP intervention. Finally, the economic evaluation of guided 
discontinuation strategy provides no clear economic support for implementing such 
an approach, although there appear to be clinical advantages related to guided 
discontinuation for some of the studied patients.  
The primary aim of the studies presented in Chapters 2 to 5 was to inform decision-
makers on the cost-effectiveness of the interventions under study. The results of 
these four studies have been reported to the Dutch Ministry of Health, Welfare and 
Sport. Two of the examined interventions (HIT and Cognitive Self-Therapy) were 
eventually recommended for reimbursement within the Dutch healthcare system.  
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Methodological issues related to economic evaluation in (mental) healthcare 
 
In this section, various methodological issues encountered in the presented studies 
will be discussed. Some are more specific for economic studies in the field of 
mental healthcare, whereas others have a broader scope.  
 
Outcome measures: QALYs versus (disease-)specific health outcomes 
Guidelines on the design of economic evaluations uniformly recommend the use of 
preference-based health outcomes, in particular Quality-Adjusted Life Years 
(QALYs: 4). An important advantage of such outcomes is the possibility of directly 
comparing findings across studies and illnesses. As described in Chapter 6, only 
few published economic evaluations in mental healthcare actually included QALYs 
(5, 6), due to various methodological concerns about this outcome measure (7).  
QALYs were assessed in three of the four economic evaluations presented in this 
thesis. In the study on guided discontinuation strategy (Chapter 5), QALYs formed 
the primary outcome measure. No differences were found between QALY results 
of the two study groups, which was in line with the results of various (secondary) 
clinical outcome measures. For the other two studies (HIT in Chapter 2, PEP in 
Chapter 4), QALYs were assessed in addition to the primary health outcomes on 
which power analyses were based. In the PEP study, QALYs could only be 
assessed for some of the included patients, results generally seemed to be in 
accordance with other outcome measures favouring CAU over the basic PEP 
intervention. However, QALY results were not always consistent with other 
results. In additional economic analyses (Chapter 6) based on data collected during 
the HIT study (Chapter 2), the results of the primary health outcome selected 
during the design stage were compared with several other health outcomes, 
including QALYs. Statistically significant (and clinically relevant) differences 
between study groups were found on three of the additionally administered clinical 
outcome measures, but differences were absent for QALY results. The studies 
presented in this thesis were not designed to assess the validity of QALYs in the 
context of mental healthcare, and can therefore not lead to conclusions on this 
topic. In general, it seems advisable to interpret QALY results with some caution in 
patients with mental illness. As also stated by others (8), economic evaluations 
should never solely rely on QALYs, but at least carefully consider the results on 
additional clinical outcome measures as well.  
Most economic evaluations conducted in mental healthcare had been designed as 
cost-effectiveness studies that included single outcome measures aimed at specific 
aspects of health (5, 6). Using such outcomes could be valid in some situations, for 
instance when an intervention has a very specific objective and effects are only 
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expected on a well-defined aspect of health (9). However, for many (economic) 
studies in mental healthcare this will not be the case, and decision-makers could 
subsequently be provided with incomplete (and sometimes incorrect) information, 
as illustrated in Chapter 6. It was suggested to try to aim for the use of instruments 
assessing overall well-being or Quality of Life (QoL), by means of generic QoL 
instruments, or otherwise disease-specific QoL instruments. However, in order to 
allow priority decisions by decision-makers on a broader or even national level, for 
instance by means of league tables for comparable or related illnesses (10), the 
same (preference-based) outcome measure has to be applied in all the studies 
concerned. For advocates of such an approach, it is important to eventually reach 
consensus among economic analysts and clinicians in the field of mental healthcare 
on the use of a generic (preference-based) health outcome in economic evaluation. 
League tables are currently not explicitly used in the decision-making process in 
the Netherlands, where reimbursement decisions generally concern alternative 
interventions directly compared in a specific economic evaluation. In the present 
situation, it seems to be more important that a primary health outcome applied in 
economic evaluation can reliably assess (changes in) health in specific patient 
populations, than to enable comparisons across various illnesses or economic 
studies.  
 
Power analysis and clinical differences between study groups  
Due to ethical reasons, power analyses in economic evaluations are usually based 
on clinical outcomes in the patient population under study, and not on costs (11). 
Consequently, most economic studies are underpowered to identify statistically 
significant differences in costs, since the skewed distribution of costs (and high 
variance) requires larger sample sizes than comparisons of clinical outcomes.  
For three of the four presented studies (HIT, Cognitive Self-Therapy, PEP), power 
analyses conducted during the design stage of each study were based on 
characteristics of outcome measures aimed at specific aspects of health in the 
patient populations under study. In the fourth study (discontinuation strategy), 
power analyses focused on utilities from which QALYs were derived. 
Unexpectedly, in none of the studies could significant differences between groups 
be demonstrated on the primary health outcome, despite the fact that sample sizes 
were in accordance with performed power analyses.  
There are various possible explanations for the absence of expected significant 
differences on primary outcome measures. In all the studies, the interventions were 
compared with CAU as provided by healthcare professionals in the Netherlands. In 
practice, there appeared to be a large variety in treatments provided under the 
heading of CAU. Many patients in the CAU conditions received more intensive 
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treatment than expected, which might explain the smaller differences between 
CAU and the studied interventions. Furthermore, analyses were mainly conducted 
in accordance with the intention-to-treat principle, i.e. all patients were included in 
the analyses regardless of whether they continued in the trial or received the 
intervention to which they were randomly assigned. This is by many considered to 
be a justified pragmatic approach for analysing data of trials (12). However, it is 
most likely to lead to lower estimates of the effect of (experimental) interventions 
than in more controlled settings, like for instance in pilot studies. In several studies, 
power analyses were based on information collected in pilot studies, where patient 
drop-out was limited and practically all the patients received the examined 
intervention. In a recent paper (13), it was demonstrated that actual effect sizes are 
commonly overestimated in pilot studies, which may lead to underpowered 
randomised clinical trials. A careful and more conservative interpretation of the 
results of pilot studies may lead to better estimates of required sample sizes. 
Another aspect that is relevant for the discussion on power analyses and clinical 
differences concerns the design of a study. All the four studies presented in this 
thesis were designed as superiority trials. A superiority design is applied when 
researchers expect to find relevant and significant clinical differences between 
study groups receiving different interventions or treatments. Alternative study 
designs are less common for clinical trials, but may be more relevant in some 
situations (14). When an intervention is expected to be associated with clinical 
effects comparable to standard treatment, but at the same time may lead to other 
(economic) benefits, one could consider using a non-inferiority design. Non-
inferiority designs intend to show that an intervention is at least equal to an 
alternative in terms of effectiveness (15). Based on a recent literature overview 
(16), it seems that a non-inferiority design would be appropriate for (economic) 
studies on self-help treatments or therapies. 
 
Length of follow-up periods and registration of costs 
Follow-up periods of economic evaluations should be long enough to adequately 
capture relevant consequences of examined interventions. Unfortunately, many 
economic evaluations conducted in mental healthcare followed patients for only a 
limited amount of time. For instance, the time horizon of various published 
economic studies in patients with depression and comorbid anxiety disorders 
typically ranged from 3 to 8 months (17, 18). Conclusions based on such short 
study periods should be interpreted with caution, especially since initial positive 
consequences of psychiatric interventions may diminish over time (19).  
The follow-up duration of the studies presented in this thesis ranged from 18 (HIT, 
Cognitive Self-Therapy, discontinuation strategy) to 36 months (PEP). Shorter 
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follow-up periods would have overestimated either clinical or economic benefits 
related to the HIT and the Cognitive Self-Therapy intervention, respectively. In the 
HIT study, there was a statistically significant difference between groups after 9 
months on the primary outcome measure in favour of HIT, which was, however, no 
longer present at 18 months after inclusion. In the study on Cognitive Self-
Therapy, healthcare utilisation decreased substantially in both study groups 
between 6 and 12 months after inclusion, which was most pronounced in the 
Cognitive Self-Therapy group. However, costs increased again for both groups in 
the last 6 months of the study. From the current findings, it seems that follow-up 
periods of at least 12 to 18 months should be used for economic studies in the field 
of mental healthcare. When focusing on specific symptoms or signs of mental 
illness expected to occur over a longer period of time, like recurrences or relapses 
in depression (20, 21), even longer follow-up periods may be indicated.  
In all the presented studies, most information on relevant cost aspects was collected 
by means of a questionnaire, administered to the patients in a face-to-face 
interview setting. The reliability of information on costs gathered with 
questionnaires appears to be negatively related to the recall period applied, as 
suggested by a recent study (22). In that study, it was concluded that recall periods 
of questionnaires should not exceed the previous 6 months. This was the case for 
two of the studies included in this thesis. Questionnaires focused on the previous 6 
months in the Cognitive Self-Therapy study, and on the previous 3 months in the 
study on PEP. In the studies on HIT and discontinuation strategy, recall periods 
were confined to the previous 9 months. Since the questionnaires were 
administered in an interview setting, the interviewer could provide patients with 
additional information when needed and could make sure that all the questions 
were answered. Consequently, there was few missing information when 
questionnaires could be administered to patients. Furthermore, patients were 
requested to bring their agenda to the interview (for instance, with information on 
previous visits to various healthcare professionals) as well as medication 
prescriptions, which may have had positive consequences for the reliability of cost 
data collected through patients.  
 
The inclusion and quantification of costs related to productivity losses 
All the presented studies were conducted from a societal perspective, i.e. a wide 
range of costs in and outside the healthcare sector was included in the analyses. 
This section will specifically focus on costs related to productivity losses. This type 
of non-medical costs can have a large influence on the total amount of costs in 
economic studies, also in mental healthcare (23). Over the years, there have been 
many debates on the inclusion and monetary quantification of productivity losses 
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due to illness-related absence from work (9). It is widely acknowledged that 
alternative approaches commonly applied for quantifying productivity losses in 
economic evaluations may lead to huge differences in estimated costs (24). The 
human capital approach, for instance, assumes that costs of lost productivity can be 
estimated by the reduced income of the individual involved. In case of mortality (or 
permanent incapacity for work), costs are calculated until the retirement age. When 
using the friction cost method (25), productivity losses are assumed to be confined 
to the period needed to replace the sick worker. This period is currently estimated 
at approximately five months in the Netherlands. Not surprisingly, costs of 
productivity losses are generally much larger when assessed with the human capital 
approach. It is currently acknowledged that, regardless of the quantification method 
applied, costs related to productivity losses can be largely overestimated when 
compensating mechanisms are not taken into account (26). In many situations, for 
instance, most of the work of people who are (temporary) absent is in practice 
completed by colleagues during regular working hours. Furthermore, a substantial 
part of the work can often be compensated by the person involved after returning to 
work. 
In the presented economic evaluations, information was collected on the type of 
employment, duration of absence, and the return to work after illness-related 
absenteeism in the patient populations concerned. Results demonstrated that only 
few patients with chronic schizophrenia (Chapter 2) had paid work, and those who 
did often worked only for a couple of hours per week in sheltered positions. The 
number of patients who worked part-time (<35 hours per week) was also 
considerable in the other studies (Chapters 3-5), where the proportion of patients 
with paid work who had a part-time job ranged from 60% to 70%. This is in sharp 
contrast with 35% part-timers in the regular working population (27). Another 
aspect concerns the return to work after a period of absence. More than half of the 
patients with schizophrenia and depression indicated that they gradually increased 
working hours (often over a period of several months) after absenteeism, before 
working in accordance with contract hours again. In several studies, initial 
differences between groups were found in the number of patients with paid work, 
which complicated the interpretation of productivity costs, especially in the study 
on DRP. Consequently, a conservative approach to the friction cost method was 
applied, where sensitivity analyses focused on the in- and exclusion of productivity 
losses. Conclusions based on the results of these sensitivity analyses were generally 
comparable to conclusions based on the standard economic analyses conducted in 
each study.  
Currently, a study is being conducted in the Netherlands that focuses on the 
Individual Placement and Support model for vocational rehabilitation in people 
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with severe mental illness. Costs related to productivity losses will play an 
important role in the economic evaluation that is part of the study design. An 
accompanying HTA methodology study will specifically focus on the 
quantification of productivity losses in this population, which is expected to lead to 
adjustments of available approaches that could be applied in other mental 
healthcare studies as well. These adjustments include a more flexible approach 
towards the period during which productivity losses are quantified.  
 
Handling missing data in economic evaluations 
Results of longitudinal studies can be biased by missing data due to patients who 
drop out or are lost to follow-up, especially if their missingness is not completely at 
random (28). The potential bias related to missing data has now also been 
acknowledged in the area of economic evaluation (29). Economic evaluations in 
mental healthcare may be confronted with considerable drop-out of patients, as was 
for instance the case in several recently conducted economic studies focusing on 
depression in primary care (30).  
Various approaches to account for missing data were applied in the studies 
combined in this thesis. An example of a simple approach is complete case 
analysis, in which patients with one or more missing measurements are excluded 
from the analyses. The correctness of applying this form of analysis largely 
depends on the type of missingness and the amount of missing data. Longitudinal 
analyses in the HIT study (Chapter 2) were in accordance with a complete case 
approach, 17% of the randomised patients for whom at least one of the 
measurements was missing were excluded from the analyses. In two of the 
conducted studies (Cognitive Self-Therapy in Chapter 3, discontinuation strategy 
in Chapter 5), mixed model techniques were used for longitudinal analyses of costs 
and health outcomes. Mixed model techniques use all available information, i.e. 
also of patients for whom one or more measurements are missing. In the studies on 
Cognitive Self-Therapy and discontinuation strategy, cost data was complete for, 
respectively, 79% and 89% of the included patients. In the PEP study (Chapter 4), 
missing data posed a particular problem; for less than half of the included patients 
with depression could costs be assessed at all the measurements. In this study, the 
expectation maximisation algorithm with a bootstrap approach was applied. This 
approach is currently considered to be one of the preferred methods for handling 
missing cost data (31).  
When the number of missing data is limited and missingness appears to be 
completely at random, methods like complete case analysis may still be valid. 
However, in many situations analysts will have to apply more advanced 
approaches. Careful examination of the data, with specific attention to the amount 
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and pattern of missingness, will provide the information needed to select adequate 
methods to deal with the problem that incomplete data may pose in various cost 




Recommendations for economic evaluations in mental healthcare 
 
Based on the methodological issues discussed above and the findings of the 
conducted studies, the following recommendations are proposed for future 
economic evaluations and related research in mental healthcare: 
 
• Cost-effectiveness studies in mental healthcare should apply generic or 
disease-specific QoL instruments, instead of instruments aimed at specific 
aspects of health. Various aspects directly related to QALYs, like the validity 
of instruments from which QALYs are derived, should be adequately assessed 
in patient populations with mental illness, given current concerns about the 
use of QALYs in mental healthcare. 
 
• Both the available literature and current findings suggest that in order to 
perform adequate power analyses, potential effects of interventions should be 
carefully examined. This is particularly important when using the results of 
pilot studies. A non-inferiority design seems to be most appropriate for 
economic studies examining self-help interventions in mental healthcare. 
 
• In order to assess all the relevant economic and clinical consequences of 
interventions, economic evaluations in mental healthcare should register costs 
and health outcomes for at least 12 to 18 months. Shorter follow-up periods 
may lead to incorrect estimations, as indicated by the results of two of the 
conducted studies. The reliability of cost data could be improved by limiting 
recall periods of questionnaires to the previous 6 months, or to administer 
questionnaires on costs by means of face-to-face interviews with the patients, 
for which patients are requested to bring their agenda.  
 
• Productivity costs can be substantial in mental healthcare and estimates of 
these costs can vary considerably between commonly applied quantification 
methods. Initial differences between treatment conditions in the number of 
patients with paid work may lead to interpretational difficulties, as 
encountered in this thesis. Based on the current findings, it seems to be highly 
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relevant to provide decision-makers with information on the consequences of 
in- and excluding costs related to productivity losses.  
 
• Patient drop-out can be considerable in studies in the area of mental 
healthcare. Especially studies with long follow-up periods and a large number 
of assessments over time may be confronted with missing data, as was the 
case for one of the conducted studies. Various approaches to handle missing 
data are currently available, which will in many situations be more appropriate 






The increasing (international) awareness of the burden and costs associated with 
mental illness has resulted in a growing number of economic evaluations and 
publications in this field of expertise worldwide. The economic evaluations 
combined in this thesis provided information to support policy decisions in the 
Netherlands, and subsequently led to positive reimbursement recommendations for 
two of the four examined interventions (HIT and Cognitive Self-Therapy). In 
recent years, several studies conducted in other countries have also demonstrated 
encouraging clinical and economic results of interventions focusing on mental 
illness. These interventions could prove to be relevant for the treatment of patients 
in the Netherlands as well. In the UK, for instance, computerised cognitive 
behavioural therapy is currently recommended as an evidence based, cost-effective 
intervention in the treatment of patients with mild to moderate depression and 
anxiety (32). It seems relevant to compare economic aspects of computerised 
cognitive behavioural therapy with other self-help strategies, like the CST 
intervention examined in this thesis (Chapter 3). Since there are large differences 
between countries in the structure of healthcare systems, available regular care, and 
methods used to assess costs, it is difficult to directly apply results of economic 
studies conducted in other countries to the situation in the Netherlands, and vice 
versa. In many cases, detailed (prospective) economic evaluations will have to be 
conducted in the healthcare system concerned to adequately (re-)evaluate the cost-
effectiveness of promising interventions. A recent (model-based) study focused on 
the economic and clinical consequences of various family interventions in the 
treatment of patients with schizophrenia in the Australian healthcare system (33). 
Results suggested that implementation of these interventions in Australia is most 
likely to be cost-effective. However, it is doubtful whether that will also be the case 
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for the Netherlands, where family interventions are already more commonly 
provided by healthcare professionals. Behavioural family treatment was, for 
instance, one of the treatment options integrated in the HIT intervention described 
in Chapter 2.  
Results from studies that did not find differences between economic aspects of 
alternative interventions are of scientific importance as well, and may prevent other 
studies from focusing on topics for which there appears to be little room for 
economic benefits. Several economic evaluations have recently examined the cost-
effectiveness of a wide range of interventions for primary care patients with 
depression in the Netherlands (30). These interventions included two pharmacy-
based approaches, a disease management programme, and Interpersonal Therapy. 
Results indicated that none of the studied interventions was cost-effective in 
comparison with regular care provided by general practitioners. Conclusions of 
these studies are comparable to those of the study on PEP (Chapter 4) that aimed to 
prevent recurrences in primary care patients with depression. It seems to be 
difficult to develop interventions for the treatment of depression that are more 
(cost-)effective than the care currently provided by GPs.  
Although the use of atypical antipsychotics is nowadays widely recommended for 
the treatment of schizophrenia and first onset psychosis, published economic 
evaluations demonstrate conflicting results when comparing various (a)typical 
antipsychotics (34). Detailed economic studies with long term follow-up periods 
are still frequently initiated to examine the economic aspects of various types of 
medication in chronic and first onset schizophrenia. It may prove to be worthwhile 
for economic studies on this topic to start focusing more on subgroups of patients 
that may benefit from specific types of medication. For instance, the study on 
alternative medication strategies in first onset psychosis (Chapter 5) was unable to 
find overall differences between guided discontinuation and maintenance 
treatment. However, a minority of the patients successfully discontinued the use of 
antipsychotics during the study, without negative economic consequences.  
Further implementation of interventions that are proven to be cost-effective is 
needed to improve the well-being of individuals and to optimise the use of scarce 
healthcare resources. Unfortunately, the actual implementation of cost-effective 
interventions in healthcare systems is often complicated (35, 36). The CHOICE 
programme of the World Health Organization (37) aims to improve the 
implementation of cost-effective interventions worldwide and illustrates the burden 
that could potentially be averted. Such initiatives are important in raising 
awareness among decision-makers about the benefits that can be gained from 
providing these interventions to patients with mental illness. Presently, the Dutch 
government stimulates research on various aspects of the implementation of cost-
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effective interventions. An ongoing study aims at the implementation of the HIT 
intervention (Chapter 2) in nine mental healthcare centres across the Netherlands. 
This study additionally tries to identify factors that may either complicate or 
facilitate the implementation of new interventions in mental healthcare in general.  
To conclude, the relevance of detailed economic evaluations to support policy 
decisions in the area of mental healthcare seems to be widely acknowledged in the 
Netherlands nowadays. Various psychosocial and psychopharmacological 
interventions for patients with mental illness were closely examined in economic 
studies in the last decade, and economic studies of promising interventions in 
mental healthcare will remain to be important for decision-making in future years. 
More (research) attention should be focused on the actual implementation of 
interventions, which is also stimulated by the Dutch government. The availability 
of cost-effective interventions needs to be improved, so that both society and 
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